Empowering Healthcare Professionals: Championing Newborn Screening for Healthier Starts

Empowering Healthcare Professionals: Championing Newborn Screening for Healthier Starts

advanced divider

Every newborn deserves a healthy start, and as a healthcare professional, you hold the key to making this a reality. Your knowledge, advocacy, and dedication play a pivotal role in ensuring that newborn screening becomes a cornerstone of paediatric healthcare. 

Advocacy by Healthcare Professionals

Your role in advocating for newborn screening begins even before a baby is born. As obstetricians and midwives, you can inform expectant parents about the significance of newborn screening during pregnancy. This early introduction sets the stage for informed decision-making.

Once the baby arrives, a well-coordinated team of healthcare experts comes into play. Phlebotomists, paediatric, and neonatal nurses ensure that samples are collected correctly, a critical step in the process. Highly trained scientists then analyse the sample at the NMP testing lab, whereafter pathologists and medical scientists at the same facility interpret results accurately, identifying genetic, metabolic, and congenital disorders.

Paediatricians and newborn screening program coordinators further contribute by communicating with parents, providing continuous education, and advocating for the program’s importance. By creating awareness and sharing knowledge, you ensure that newborn screening remains a priority in paediatric healthcare.

Educating Families about Newborn Screening

One of your primary responsibilities as a healthcare professional is to impart knowledge to parents and caregivers about newborn screening’s significance and potential benefits. Here are practical ways to achieve this:

1. Clear and Accessible Information: Provide families with written materials, brochures, and pamphlets that explain newborn screening in simple terms. You can contact us via the NMP website anytime to request these materials. 

2. Online Resources: Direct parents to reliable online resources and websites such as the NMP and Next Biosciences offering additional information about newborn screening and related conditions.

3. Real-Life Stories: Share success stories or testimonials of infants whose lives were positively impacted by early detection through newborn screening. These stories make the benefits tangible and relatable.

Your Dedication makes a visible difference

Real-life cases illustrate the power of early detection. One such case involved a baby diagnosed with a metabolic disorder through newborn screening. The test enabled an accurate and prompt diagnosis, leading to life-saving medical care. Without these essential tests, this critical intervention might have been missed.

Staying Informed

Staying updated on developments in newborn screening technologies and practices is crucial. Continuous education is vital. Achieve this by participating in workshops, seminars, and conferences related to newborn screening. Follow NMP and Next Biosciences on various social media platforms to stay abreast of the latest opportunities.

A Message of Appreciation

In closing, we want to express our heartfelt appreciation to the healthcare professionals who have already become champions of newborn screening. Your knowledge, empathy, and unwavering support are the cornerstones of this vital program’s success. You are the heroes who silently work behind the scenes, making a profound impact on the lives of newborns and their families.

If you just learned about newborn screening and want to join us, please don’t hesitate to get in touch. You will not only be shaping a healthier future for infants, but also make a profound impact on families and communities. Your work extends beyond hospital walls, reaching into homes, hearts, and futures.

accelRare® is a pre-diagnostic solution for rare diseases. accelRare® uses the medvir tool, certified as a Class I medical device, for which Medical Intelligence Service is the manufacturer and Sanofi the distributor.

Receive the Form with PDF Attachment

To obtain a copy of this form as PDF attachment for printing, please provide your email address below.

Provide clinical information

Clinical information may greatly assist in the interpretation of metabolic results and additional recommendations. The clinical information can be provided here

Print the test selection form from email and hand to the patient or phlebotomist for sample collection

[field id="reference_id"]
[field id="imdclinicalresult1"]

The National Metabolomics Platform is a specialized laboratory dedicated to diagnosing rare and inherited metabolic diseases. Located on the Potchefstroom campus of North-West University, the laboratory may occasionally require additional tests, including genetic testing, to confirm a diagnosis. If these tests incur additional costs, the laboratory will seek prior approval from you and/or your clinician. To ensure diagnostic accuracy, clinical information and other reports may also be requested. Such requests are made solely to enhance the precision of the diagnosis. Following a diagnosis, the laboratory may contact you about potential research projects for which you might be eligible. These projects aim to improve the understanding and characterization of rare diseases and offer patients opportunities to participate in international clinical trials. Participation in these projects is entirely voluntary, and there is no obligation to take part if contacted. All research is conducted under the oversight of the NWU Health Research Ethics Committee.

GCxGC-TOFMS Untargeted

Compound list

Spectra identified via comparison with library spectra

NMR Untargeted

Compound list

Spectra identified via comparison with library spectra

LDL Cholesterol Subfractions

Compound list

The LDL subfraction test measures up to twelve lipoprotein fractions and subfractions (VLDL, mid-bands A-C and LDL 1 through 7)

HDL Cholesterol Subfractions

Compound list

Separates and quantifies up to 10 HDL subfractions, classified from large buoyant HDL lipoproteins (HDL-L) to small-dense HDL lipoproteins (HDL-S).